The cathelicidin-derived tritrpticin enhances the efficacy of ertapenem in experimental rat models of septic shock

Shock

Volumn 26, Issue 2, 2006, Pages 195-200

  Ghiselli, Roberto ^a   Cirioni, Oscar ^a   Giacometti, Andrea ^a,c   Mocchegiani, Federico ^a   Orlando, Fiorenza ^b   Silvestri, Carmela ^a   Licci, Alberto ^a   Della Vittoria, Agnese ^a   Scalise, Giorgio ^a   Saba, Vittorio ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b INRCA   (Italy)

^c c/o Ospedale Regionale ^*  (Italy)

Author keywords

Antimicrobial peptides; Cathelicidins; Lipopolysaccharide; LPS; Sepsis; Septic shock; Tritrpticin

Indexed keywords

CATHELICIDIN; CYTOKINE; ENDOTOXIN; ERTAPENEM; INTERLEUKIN 6; SODIUM CHLORIDE; TRITRIPTICIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GROWTH; BLOOD; CONTROLLED STUDY; DRUG EFFICACY; ESCHERICHIA COLI; LETHALITY; LIVER; MALE; MESENTERY LYMPH NODE; NONHUMAN; PERITONEUM; PLASMA; RAT; SEPSIS; SEPTIC SHOCK; SEROTYPE; SPLEEN;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BETA-LACTAMS; CECUM; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; ENDOTOXINS; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; INTERLEUKIN-6; LIGATION; MALE; MICROBIAL SENSITIVITY TESTS; OLIGOPEPTIDES; RATS; RATS, WISTAR; SHOCK, SEPTIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33746739472     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.shk.0000225407.24479.3f     Document Type: Article

References (42)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29: 1303-1310, 2001.
2. Diekema DJ, Pfaller MA, Jones RN, Doern GV, Winokur PL, Gales AC, Sader HS, Kugler K, Beach M: Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. Clin Infect Dis 29:595-607, 1999.
3. Edgeworth JD, Treacher DF, Eykyn SJ: A 25-year study of nosocomial bacteremia in an adult intensive care unit. Crit Care Med 27:1421-1428, 1999.
4. Wenzel RP, Pinsky MR, Ulevitch RJ, Young L: Current understanding of sepsis. Clin Infect Dis 22:407-413, 1996.
5. Bochud PY, Calandra T: Pathogenesis of sepsis: new concepts and implications for future treatment. BMJ 326:262-266, 2003.
6. Bone RC: Pathophysiology of sepsis. Ann Intern Med 115:457-469, 1991.
7. Akashi S, Saitoh S, Wakabayashi Y, Kikuchi T, Takamura N, Nagai Y, Kusumoto Y, Fukase K, Kusumoto S, Adachi Y, et al: Lipopolysaccharide interaction with cell surface toll-like receptor 4-MD-2: higher affinity than that with MD-2 or CD14. J Exp Med 198:1035-1042, 2003.
8. Yethon JA, Whitfield C: Lipopolysaccharide as a target for the development of novel therapeutics in gram-negative bacteria. Curr Drug Targets Infect Disord 1:91-106, 2001.
9. Meng G, Rutz M, Schiemann M, Metzger J, Grabiec A, Schwandner R, Luppa PB, Ebel F, Busch DH, Bauer S, et al: Antagonist antibody prevents toll-like receptor 2-driven lethal shock-like syndromes. J Clin Invest 113:1473-1481, 2004.
10. Yibin G, Jiang Z, Hong Z, Gengfa L, Liangxi W, Guo W, Yongling L: A synthetized cationic tetradecapeptide from hornet venom kills bacteria and neutralizes lipopolysaccharide in vivo and in vitro. Biochem Pharmacol 70:209-219, 2005.
11. Ulevitch RJ, Tobias PS: Recognition of gram-negative bacteria and endotoxin by the innate system. Curr Opin Immunol 11:19-22, 1999.
12. Glauser MP, Zanetti G, Baumgartner JD, Cohen J: Septic shock: pathogenesis. Lancet 338:732-736, 1991.
13. Hack CE, Aarden LA, Thijs LG: Role of cytokines in sepsis. Adv Immunol 66:101-195, 1997.
14. Hardaway RM: A review of septic shock. Am Surg 66:22-29, 2000.
15. Remick DG, Ward PA: Evaluation of endotoxin models for the study of sepsis. Shock 24:7-11, 2005.
16. Yin K, Gribbin E, Wang H: Interferon-gamma inhibition attenuates lethality after cecal ligation and puncture in rats: implication of high mobility group box-1. Shock 24:396-401, 2005.
17. Newcomb D, Bolgos G, Green L, Remick DG: Antibiotic treatment influences outcome in murine sepsis:mediators of increased morbidity. Shock 10:110-117, 1998.
18. Cohen J, McConnell JS: Antibiotic-induced endotoxin release. Lancet 2:1069-1070, 1985.
19. Prins JM, Kuijper EJ, Mevissen MLCM, Speelman P, van Deventer SJH: Release of tumor necrosis factor alpha and interleukin 6 during antibiotic killing of Escherichia coli in whole blood: influence of antibiotic class, antibiotic concentration, and presence of septic serum. Infect Immun 63:2236-2242, 1995.
20. Byl B, Clevenbergh P, Kentos A, Jacobs F, Marchant A, Vincent JL, Thys JP: Ceftazidime- and imipenem-induced endotoxin release during treatment of gram-negative infections. Eur J Clin Microbiol Infect Dis 20:804-807, 2001.
21. Glauser MP, Zanetti G, Baumgartner JD, Cohen J: Septic shock: pathogenesis. Lancet 338:732-736, 1991.
22. Cannon M: A family of wound healers. Nature 328:478, 1987.
23. Hancock REW: Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect Dis 1:156-164, 2001.
24. Hancock REW, Scott MG: The role of antimicrobial peptides in animal defenses. Proc Natl Acad Sci U S A 97:8856-8861, 2000.
25. Gough M, Hancock REW, Kelly NM: Antiendotoxin activity of cationic peptide antimicrobial agents. Infect Immun 64:4922-4927, 1996.
26. Zanetti M: Cathelicidins, multifunctional peptides of the innate immunity. J Leukoc Biol 75:39-48, 2004.
27. Zanetti M, Gennaro R, Romeo D: Cathelicidins: a novel protein family with common proregion and a variable C-terminal antimicrobial domain. FEBS Lett 374:1-5, 2001.
28. Schibli DJ, Hwang PM, Vogel HJ: Structure of the antimicrobial peptide tritrpticin bound to micelles: a distinct membrane-bound peptide fold. Biochemistry 38:16749-16755, 1999.
29. Salay LC, Procopio J, Oliveira E, Nakaie CR, Schreier S: Ion channel-like activity of the antimicrobial peptide tritrpticin in planar lipid bilayers. FEBS Lett 565:171-175, 2004.
30. DiNubile MJ, Friedland I, Chan CY, Motyl MR, Giezek H, Shivaprakash M, Weinstein RA, Quinn JP: Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdomnal infections: observations from two randomized comparative clinical trials of ertapenem therapy. Eur J Clin Microbiol Infect Dis 24:443-449, 2005.
31. Clinical and Laboratory Standards Institute (CLSI) 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard M7-A6. Villanova, PA.
32. Odds FC: Synergy, antagonism and what the chequerboard puts between them. J Antimicrob Chemother 52:1, 2003.
33. Rivers EP, McIntyre L, Morro DC, Rivers KK: Early and innovative interventions for severe sepsis and septic shock: taking advantage of a window of opportunity. CMAJ 173:1054-1065, 2005.
34. Kumar A, Anel RL: Experimental and emerging therapies for sepsis and septic shock. Expert Opin Investig Drugs 10:1471-1485, 2001.
35. Boman HG: Antibacterial peptides: basic facts and emerging concepts. J Int Med Res 254:197-215, 2003.
36. Ghiselli R, Giacometti A, Cirioni O, Circo R, Mocchegiani F, Skerlavaj B, D'Amato G, Scalise G, Zanetti M, Saba V: Neutralization of endotoxin in vitro and in vivo by Bac7(1-35), a proline-rich antibacterial peptide. Shock 19:577-581, 2003.
37. Giacometti A, Cirioni O, Ghiselli R, Mocchegiani F, D'Amato G, Circo R, Orlando F, Skerlavaj B, Silvestri C, Saba V, et al: Cathelicidin peptide sheep myeloid antimicrobial peptide-29 prevents endotoxin-induced mortality in rat models of septic shock. Am J Respir Crit Care Med 169:187-194, 2004.
38. Blot S, Waele JJ: Crical issues in the clinical management of complicated intra-abdominal infections. Drugs 65:1611-1620, 2005.
39. Tracey KJ, Abraham E: From mouse to man: or what have we learned about cytokine-based anti-inflammatory therapies? Shock 11:224-225, 1999.
40. Yeaman MR, Yount NY: Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev 55:27-55, 2003.
41. McCafferty DG, Cudic P, Yu MK, Behenna DC, Kruger R: Synergy and duality in peptide antibiotic mechanisms. Curr Opin Chem Biol 3:672-680, 1999.
42. Vaara M, Porro M: Group of peptides that act synergistically with hydrophobic antibiotics against gram-negative enteric bacteria. Antimicrob Agents Chemother 40:1801-1805, 1996.